{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:58:02Z","timestamp":1772121482916,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ophtha.2010.04.036","type":"journal-article","created":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T04:41:38Z","timestamp":1281847298000},"page":"24-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Intralesional Rituximab"],"prefix":"10.1016","volume":"118","author":[{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Govi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Crocchiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Modorati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2010.04.036_bib1","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin's lymphoma","volume":"23","author":"Fisher","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ophtha.2010.04.036_bib2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnci\/djj248","article-title":"Rapidly increasing incidence of ocular non-Hodgkin lymphoma","volume":"98","author":"Moslehi","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ophtha.2010.04.036_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1442-9071.2001.d01-18.x","article-title":"Ocular adnexal lymphoproliferative disease: a series of 73 cases","volume":"29","author":"McKelvie","year":"2001","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib4","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0161-6420(98)98024-1","article-title":"Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases","volume":"105","author":"Coupland","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.036_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","author":"Ferreri","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14656566.8.8.1073","article-title":"Therapeutic management of ocular adnexal MALT lymphoma","volume":"8","author":"Ferreri","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ophtha.2010.04.036_bib7","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1200\/JCO.2005.07.083","article-title":"Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy","volume":"23","author":"Ferreri","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial","volume":"98","author":"Ferreri","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ophtha.2010.04.036_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10792-007-9102-5","article-title":"Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy","volume":"28","author":"Yu","year":"2008","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0161-6420(00)00591-1","article-title":"Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report","volume":"108","author":"Blasi","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.036_bib11","first-page":"284","article-title":"Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b","volume":"118","author":"Lachapelle","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib12","first-page":"1578","article-title":"Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa [letter]","volume":"90","author":"Ferreri","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ophtha.2010.04.036_bib13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia","volume":"66","author":"Cvetkovic","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.ophtha.2010.04.036_bib14","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2010.04.036_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2010.04.036_bib16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1046\/j.1365-2133.2001.04241.x","article-title":"Intralesional rituximab for cutaneous B-cell lymphoma","volume":"144","author":"Paul","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2133.2005.06433.x","article-title":"Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma","volume":"152","author":"Roguedas","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-8140(00)00328-5","article-title":"Orbital lymphoma: radiotherapy outcome and complications","volume":"59","author":"Stafford","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/08820530500351694","article-title":"Topical medical therapies for ocular surface tumors","volume":"21","author":"Poothullil","year":"2006","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00347-008-1800-5","article-title":"Topical mitomycin C as a therapy of conjunctival tumours [in German]","volume":"105","author":"Schallenberg","year":"2008","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.ophtha.2010.04.036_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/IOP.0b013e3181ac4c39","article-title":"Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia","volume":"25","author":"Ballalai","year":"2009","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2010.04.036_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.1984","article-title":"Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions","volume":"209","author":"Chanudet","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdl027","article-title":"Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa","volume":"17","author":"Ferreri","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1349-7006.2006.00138.x","article-title":"Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab","volume":"97","author":"Takami","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ophtha.2010.04.036_bib27","first-page":"1225","article-title":"Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit","volume":"120","author":"Esmaeli","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-0609.2004.00299.x","article-title":"Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva","volume":"73","author":"Nuckel","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ophtha.2010.04.036_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.IOP.0000115594.98470.AC","article-title":"Monoclonal antibody treatment of orbital lymphoma","volume":"20","author":"Sullivan","year":"2004","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2010.04.036_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.leukres.2004.05.011","article-title":"Rituximab in primary conjunctiva lymphoma","volume":"29","author":"Zinzani","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.ophtha.2010.04.036_bib31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdn692","article-title":"Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma","volume":"20","author":"Esmaeli","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642010005099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642010005099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:00:12Z","timestamp":1758981612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642010005099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0161642010005099"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.036","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9583956.10908054","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.9583956.10244054","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.9583956.10802056","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.9583956.10360054","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intralesional Rituximab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}